Combinations of DDR1 inhibitors and classical chemotherapeutics reduce tumor burden in orthotopic xenograft and orthotopic pancreatic cancer models (Aguilera et al., 2017). This evidence concerns the gene DDR1 and pancreatic neoplasm.